Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
Total Valuation
Aardvark Therapeutics, Inc. has a market cap or net worth of $303.08M. The enterprise value is $163.19M.
Market Cap$303.08M
Enterprise Value$163.19M
Share Statistics
Aardvark Therapeutics, Inc. has 21,773,272 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,773,272
Owned by Insiders42.42%
Owned by Institutions26.38%
Financial Efficiency
Aardvark Therapeutics, Inc.’s return on equity (ROE) is 0.38 and return on invested capital (ROIC) is -31.10%.
Return on Equity (ROE)0.38
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-31.10%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-935.82K
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aardvark Therapeutics, Inc. is ―. Aardvark Therapeutics, Inc.’s PEG ratio is -0.05.
PE Ratio―
PS Ratio0.00
PB Ratio-3.38
Price to Fair Value-3.38
Price to FCF-10.15
Price to Operating Cash Flow-4.51
PEG Ratio-0.05
Income Statement
In the last 12 months, Aardvark Therapeutics, Inc. had revenue of 0.00 and earned -20.59M in profits. Earnings per share was -1.59.
Revenue0.00
Gross Profit0.00
Operating Income-22.79M
Pretax Income-20.59M
Net Income-20.59M
EBITDA-22.65M
Earnings Per Share (EPS)-1.59
Cash Flow
In the last 12 months, operating cash flow was -47.48M and capital expenditures -101.00K, giving a free cash flow of -47.58M billion.
Operating Cash Flow-47.48M
Free Cash Flow-47.58M
Free Cash Flow per Share-2.19
Dividends & Yields
Aardvark Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-0.60%
50-Day Moving Average12.07
200-Day Moving Average―
Relative Strength Index (RSI)45.04
Average Volume (3m)166.37K
Important Dates
Aardvark Therapeutics, Inc. upcoming earnings date is Apr 6, 2026, After Close (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateApr 6, 2026
Ex-Dividend Date―
Financial Position
Aardvark Therapeutics, Inc. as a current ratio of 15.05, with Debt / Equity ratio of 0.45%
Current Ratio15.05
Quick Ratio15.05
Debt to Market Cap<0.01
Net Debt to EBITDA2.96
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aardvark Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aardvark Therapeutics, Inc. EV to EBITDA ratio is -6.02, with an EV/FCF ratio of -6.81.
EV to Sales0.00
EV to EBITDA-6.02
EV to Free Cash Flow-6.81
EV to Operating Cash Flow-6.85
Balance Sheet
Aardvark Therapeutics, Inc. has $126.35M in cash and marketable securities with $545.00K in debt, giving a net cash position of $125.81M billion.
Cash & Marketable Securities$126.35M
Total Debt$545.00K
Net Cash$125.81M
Net Cash Per Share$5.78
Tangible Book Value Per Share-$4.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aardvark Therapeutics, Inc. is $33.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.38
Price Target Upside139.80% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast31.30%